Federal healthcare coverage for CBD is here. Hemp product standards are still needed.

Inesa Ponomariovaite (courtesy photo)

(This is a contributed guest column. To be considered as an MJBizDaily guest columnist, please submit your request here.)

The Centers for Medicare & Medicaid Services’ (CMMS) offer of limited coverage for certain hemp-derived CBD products represents a significant shift in how the U.S. healthcare system views cannabinoids.

For patients, particularly those managing chronic pain or complex conditions, it signals a step toward broader access to alternative therapeutic options that an estimated 40 million Americans are already using.

Anti-cannabis activists are mounting a legal challenge. Their lawsuit frames the issue as a binary: patient access versus public safety. But that argument misses the larger issue.

The real question is not whether reimbursement for cannabinoid treatments should be available through programs like this. It’s whether the rules and regulations needed to support their safe, consistent and effective use are in place.

Are hemp-based CBD medicines safe and effective?

There is a growing body of research that suggests cannabinoid-based treatments may play a role in supporting patients, including those navigating opioid use disorder. Early clinical studies suggest that certain cannabinoids may help reduce withdrawal symptoms, cravings and anxiety associated with opioid abstinence.

These findings are not definitive, and they do not position cannabinoids as a standalone solution. These findings point to a role for cannabinoids as part of a broader, clinically guided approach to care.

At the same time, tens millions of American consumers are already using hemp-derived products – containing THC and CBD – outside of the healthcare system. That reality exists regardless of whether formal coverage pathways are introduced.

When patients turn to these products on their own, they often do so without consistent dosing guidance, physician oversight or a clear understanding of product quality or composition.

This is where the current moment becomes more complex. Expanding access without addressing these underlying gaps does not solve the problem. It risks reinforcing it.

How can patients verify cannabinoid medicines?

Today, there are no unified federal standards governing hemp-derived products for testing, formulation, or clinical use. Requirements vary by state, and in many cases, companies are only required to test for basic potency and label accuracy.

Comprehensive testing for contaminants such as heavy metals, pesticides, or microbial impurities is not consistently mandated. Nor is there a standardized approach to verifying consistency from batch to batch. These elements are crucial for efficacy and safety for patients.

In this environment, claims of transparency often become a marketing claim rather than a verifiable standard that products can meet. Consumers may see references to third-party testing, but access to full Certificates of Analysis, and the ability to interpret them, is not always straightforward.

This places the burden on patients to evaluate product quality themselves, which is not a reasonable expectation in a healthcare context.

If programs like the CMS pilot are going to succeed, they cannot rely on this fragmented foundation.

After marijuana rescheduling should come federal hemp cannabinoid rules

The concern should not be that hemp-derived products are entering clinical conversations. In many ways, a framework that ensures safety, consistency, and accountability at scale.

Challenging access without addressing the lack of standards does little to protect patients. At the same time, moving forward without building those standards into the system creates a different kind of risk, one where outcomes vary widely based on product quality, formulation, and oversight.

In the wake of the Justice Department’s historic reclassification of medical cannabis administered under state rules, things are already in motion. A more constructive path forward would focus on developing the infrastructure that allows cannabinoids to be evaluated and integrated responsibly.

That includes establishing clear federal guidelines for testing and quality assurance, creating more consistent labeling standards and supporting research that can inform dosing and clinical use.

It also requires collaboration between regulators, healthcare providers, researchers and industry leaders to ensure that products entering the market meet a higher bar for safety and efficacy.

There is also a responsibility within the industry itself. In the absence of clear federal direction, companies have the ability (and obligation) to hold themselves to higher standards than what is minimally required.

That means expanding testing panels, working with accredited laboratories, and making product data accessible and understandable to the public. It means treating transparency not as a differentiator, but as a baseline expectation.

The major gap

The CMS pilot represents more than a policy experiment. It reflects a broader shift in how cannabis and hemp are being viewed within healthcare: as legitimate, non-fringe tools that warrant structured evaluation.

The key question now is whether the systems surrounding these products will evolve.  Access alone is not enough. For cannabinoids to deliver meaningful public health benefits, they must be supported by standards that patients, providers, and regulators can trust.

Inesa Ponomariovaite is the founder and CEO of Nesa’s Hemp, a wellness company focused on advancing quality, transparency and product integrity in the hemp industry.